Bial ’s epilepsy drug shows clinical efficacy in real-life study

Bial and its licensee Eisai have reported positive real-life data of Zebinix (eslicarbazepine acetate) from the Euro-Esli study in patients with partial-onset seizures (POS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news